Clinical significance of high on-treatment platelet reactivity in patients with prolonged clopidogrel therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel beyond 1 year has been shown to reduce ischemic events at the expense of increased bleeding. However, limited data are available on the clinical significance of platelet reactivity (PR) at 1 year. Methods: We retrospectively identified 331 patients who underwent percutaneous coronary intervention (PCI) and assessed the on-clopidogrel PR using VerifyNow P2Y12 assay at 1 year in a single center. Two hundred eleven patients were on DAPT for > 1 year. The relationship between high on-treatment platelet reactivity (HPR) at 1 year and clinical outcomes beyond 1 year, as well as the longitudinal change in PR was analyzed. Results: At 1 year, 135 (64%) patients showed HPR and 76 (36%) did not. There was a significant increase in ischemic endpoint events, including cardiovascular death, non-fatal myocardial infarction, and stroke/transient ischemic attack in patients with compared to without HPR at 1 year (hazard ratio [HR], 2.68; 95% confidence interval [CI], 1.06 to 6.77; p = 0.036). However, the incidence of any Bleeding Academic Research Consortium bleeding was significantly lower in the HPR group (HR, 0.11; 95% CI, 0.02 to 0.65; p = 0.015). In the longitudinal analysis, PR significantly decreased from post-load to 1 year after index PCI in the non-HPR group. Conversely, the HPR group showed high PR from baseline through 1 year. Conclusions: HPR at 1 year may be a useful surrogate for predicting ischemic and bleeding events in patients on prolonged DAPT. Patients with and without HPR at 1 year showed different patterns of longitudinal change in PR.
Abstract
Background/Aims: Prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel beyond 1 year has been shown to reduce ischemic events at the expense of increased bleeding. However, limited data are available on the clinical significance of platelet reactivity (PR) at 1 year. Methods: We retrospectively identified 331 patients who underwent percutaneous coronary intervention (PCI) and assessed the on-clopidogrel PR using VerifyNow P2Y12 assay at 1 year in a single center. Two hundred eleven patients were on DAPT for > 1 year. The relationship between high on-treatment platelet reactivity (HPR) at 1 year and clinical outcomes beyond 1 year, as well as the longitudinal change in PR was analyzed. Results: At 1 year, 135 (64%) patients showed HPR and 76 (36%) did not. There was a significant increase in ischemic endpoint events, including cardiovascular death, non-fatal myocardial infarction, and stroke/transient ischemic attack in patients with compared to without HPR at 1 year (hazard ratio [HR], 2.68; 95% confidence interval [CI], 1.06 to 6.77; p = 0.036). However, the incidence of any Bleeding Academic Research Consortium bleeding was significantly lower in the HPR group (HR, 0.11; 95% CI, 0.02 to 0.65; p = 0.015). In the longitudinal analysis, PR significantly decreased from post-load to 1 year after index PCI in the non-HPR group. Conversely, the HPR group showed high PR from baseline through 1 year. Conclusions: HPR at 1 year may be a useful surrogate for predicting ischemic and bleeding events in patients on prolonged DAPT. Patients with and without HPR at 1 year showed different patterns of longitudinal change in PR.
참고문헌 (25)
- Kitamura T, "World Health Assembly agendas and trends of international health issues for the last 43 years : analysis of World Health Assembly agendas between 1970 and 2012", Health Policy, 110, pp.198~206 (2013)
- Holmes DR Jr, "Stent thrombosis", J Am Coll Cardiol, 56, pp.1357~1365 (2010)
- Mauri L, "Stent thrombosis in randomized clinical trials of drug-eluting stents", N Engl J Med, 356, pp.1020~1029 (2007)
- Valgimigli M, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)", Eur Heart J, 39, pp.213~260 (2018)
- Mega JL, "Pharmacology of antithrombotic drugs : an assessment of oral antiplatelet and anticoagulant treatments", Lancet, 386, pp.281~291 (2015)
- Wiviott SD, "Clinical evidence for oral antiplatelet therapy in acute coronary syndromes", Lancet, 386, pp.292~302 (2015)
- Stone GW, "Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents(ADAPT-DES) : a prospective multicentre registry study", Lancet, 382, pp.614~623 (2013)
- Campo G, "Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome", J Am Coll Cardiol, 57, pp.2474~2483 (2011)
- Alexopoulos D, "Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients", Int J Cardiol, 168, pp.629~630 (2013)
- Mehran R, "Standardized bleeding definitions for cardiovascular clinical trials : a consensus report from the Bleeding Academic Research Consortium", Circulation, 123, pp.2736~2747 (2011)
- Ndrepepa G, "Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention", Circulation, 125, pp.1424~1431 (2012)
- Malinin A, "Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R)rapid analyzer : the VERIfy Thrombosis risk Assessment(VERITAS)study", Thromb Res, 119, pp.277~284 (2007)
- Tantry US, "Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding", J Am Coll Cardiol, 62, pp.2261~2273 (2013)
- Price MJ, "Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention : a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay : Impact on Thrombosis and Safety(GRAVITAS)trial", Circulation, 124, pp.1132~1137 (2011)
- Breet NJ, "Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation", JAMA, 303, pp.754~762 (2010)
- Aradi D, "Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention : systematic review and meta-analysis", Am Heart J, 160, pp.543~551 (2010)
- Mauri L, "Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents", N Engl J Med, 371, pp.2155~2166 (2014)
- Trenk D, "A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents : results of the TRIGGER-PCI(Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel)study", J Am Coll Cardiol, 59, pp.2159~2164 (2012)
- Tello-Montoliu A, "Temporal changes in platelet response in acute coronary syndrome patients with prasugrel and clopidogrel after stent implantation", Circ J, 82, pp.353~360 (2018)
- Kyeong Ho Yun, "Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor", Korean Circulation Journal, 49(11), pp.1052~1061 (2019), 대한심장학회[DOI]
- Hochholzer W, "Variability of individual platelet reactivity over time in patients treated with clopidogrel : insights from the ELEVATE-TIMI 56trial", J Am Coll Cardiol, 64, pp.361~368 (2014)
- Bonaca MP, "Long-term use of ticagrelor in patients with prior myocardial infarction", N Engl J Med, 372, pp.1791~1800 (2015)
- Bhatt DL, "Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention(THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial", Lancet, 394, pp.1169~1180 (2019)
- Barbash GI, "Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction : mechanism of the"smoker’s paradox"from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries", J Am Coll Cardiol, 26, pp.1222~1229 (1995)
- Crimi G, "Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes", Platelets, 29, pp.309~311 (2018)